About Em9 Bio
At Em9 Bio, we specialize in bioconjugation process development and manufacturing — turning complexity into capability for drug developers advancing next-generation therapeutics. Built on deep expertise in antibody-drug conjugates and related modalities, our platform extends to formulation and process development for proteins and emerging biologics. With integrated, full-spectrum analytical services — including specialized bioassays — we ensure precision from concept to clinic. Our infrastructure is AI-ready, designed to accelerate insights and compress timelines, empowering your breakthrough to reach patients faster.
Who We Are
Em9 Bio is a U.S.-based contract development and manufacturing partner located in Fremont, California, founded by a team of seasoned biopharmaceutical experts. We specialize in bioconjugation and fill-finish services, offering agile, cost-effective solutions with rapid turnaround to support both preclinical (GLP) and clinical (GMP) supply needs. In a landscape often reliant on offshore vendors, EmNine Bio provides a domestic alternative — combining scientific precision, regulatory alignment, and onshore reliability to help drug developers advance complex therapeutics from idea to impact, faster and with greater confidence.
What We Do
Em9 Bio delivers end-to-end bioconjugation and fill-finish services, from early-stage process development and optimization through to GMP manufacturing. We support programs at every scale — from pilot to clinical — providing flexible supply and testing tailored to client needs. Our capabilities are fully integrated with comprehensive analytical support, powered by our dedicated GMP Center of Excellence, Valentia Analytical. Together, we ensure scientific rigor, regulatory compliance, and seamless execution across the entire development lifecycle.